NEW YORK (GenomeWeb) – GenomeDx and pathology firm Pathnostics said today that they have entered a strategic agreement under which GenomeDx will market and distribute Pathnostics' Guidance UGx and Guidance PRx tests.

The two tests diagnose urinary tract infections (UTIs) and prostatitis, respectively. Both use quantitative PCR to detect the presence of pathogens and to measure molecular signs of antibiotic resistance. According to Pathnostics, this provides a faster and more comprehensive solution than traditional culture methods.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.